The Rest Of Europe Leukapheresis Market was valued at $1.2 Million in 2026 and projected to reach to $1.6 Million by 2031, representing a compound annual growth rate of 5.9%. Rest Of Europe's leukapheresis market demonstrates moderate growth potential as healthcare systems in smaller European nations invest in hematologic treatment capabilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe's leukapheresis market is valued at $1.2 million in 2026, expanding to $1.6 million by 2031 at a CAGR of 5.9%, reflecting steady adoption across smaller European healthcare systems.
Smaller European markets are increasingly integrating leukapheresis technologies into clinical practice, driven by rising hematologic malignancy cases and growing recognition of cell therapy's therapeutic potential in the region.
Rest Of Europe is experiencing gradual modernization of oncology and hematology departments, with improved access to advanced apheresis equipment and trained personnel supporting market expansion.
Increased medical education and clinical trials in Rest Of Europe are raising awareness of leukapheresis benefits for leukemia, lymphoma, and CAR-T cell therapy preparation, accelerating market penetration.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | MULTIPLE MYELOMA (Indication) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.9% from 2026 to 2031 |
| Largest Segment | ACUTE LYMPHOCYTIC LEUKEMIA (Indication) |
| Market Size Base Year (Billions) | ~USD 0.09 (2026) |
| Revenue Forecast (Billions) | ~USD 0.14 (2031) |
| Segments Covered | Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type |
7 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| MAXCYTE, INC | United States | Public Company | ExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees, |
MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.
Rest Of Europe's leukapheresis market is estimated at $1.2 million in 2026.
Rest Of Europe's leukapheresis market is forecast to reach $1.6 million by 2031.
Rest Of Europe's leukapheresis market is expected to grow at a compound annual growth rate of 5.9% from 2026 to 2031.
Rest Of Europe's market growth is driven by increasing hematologic malignancy prevalence, expanding CAR-T cell therapy adoption, and improving healthcare infrastructure.
Rest Of Europe exhibits slower adoption rates than Western Europe due to limited healthcare infrastructure, lower clinical awareness, and smaller patient populations.
This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.
A breakdown of the primary respondents is provided below:
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.
Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics
Key Stakeholders
Report Objectives
Detailed analysis and profiling of additional market players (up to 5)
Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries
Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries
Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market
Competitive leadership mapping for established players in the US
Full forecast, segment splits, and company analysis for all Leukapheresis Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report